UNITED STATES PATENT AND TRADEMARK OFFICE

_____

BEFORE THE PATENT TRIAL AND APPEAL BOARD

_____

BLUEBIRD BIO, INC.
Petitioner

v.

SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH,
Patent Owner

_____

Patent No. 8,058,061

_____

PETITIONER'S CURRENT LIST OF EXHIBITS

LIST OF EXHIBITS

Ex. No.	Description	Previously Submitted
Ex.1001	U.S. Patent No. 8,058,061 to Sadelain *et al.* ("the '061 patent")	X
Ex.1002	Declaration of Jörg Bungert, Ph.D.	X
Ex.1003	Curriculum Vitae of Jörg Bungert, Ph.D.	X
Ex.1004	May, "Therapeutic Hemoglobin Synthesis in Beta-Thalassemic Mice Expressing Lentivirus-Encoded Beta-Globin," Cornell University (2001) ("the *May Thesis*")	X
Ex.1005	May, *et al.*, "Therapeutic Haemoglobin Synthesis in β-thalassaemic Mice Expressing Lentivirus-Encoded Human β-globin," Nature, 406:82-86 (2000) ("the *May Article*")	X
Ex.1006	May, *et al.*, "Lentiviral-Mediated Transfer of the Human β-Globin Gene and Large Locus Control Region Elements Permit Sustained Production of Therapeutic Levels of β-Globin in Long-Term Bone Marrow Chimeras," Mol. Therapy, 1(5):S248-249 (2000) ("the *May Abstract*")	X
Ex.1007	Perutz, *et al.*, "Hemoglobin Structure and Respiratory Transport," Sci. Am., 239(6): 92-125 (1978)	X
Ex.1008	Thein & Rochette, "Disorders of Hemoglobin Structure and Synthesis," *in* Principles of Mol. Med. 179 (Jameson, ed., 1998)	X
Ex.1009	Bank, *et. al*, "Disorders of Human Hemoglobin," Science, 207:486-93 (1980)	X
Ex.1010	He & Russell, "Expression, Purification, and Characterization of Human Hemoglobins Gower-I ($\zeta_2\epsilon_2$), Gower-2 ($\alpha_2\epsilon_2$), and Portland-2 ($\zeta_2\beta_2$) Assembled in Complex Transgenic-Knockout Mice, Blood, 97(4):1099-1105 (2001)	X

Ex.1011	Bunn, "Pathogenesis and Treatment of Sickle Cell Disease," N. Engl. J. Med., 337(11):762-69 (1997)	X
Ex.1012	Hardison, *et al.*, "Locus Control Regions of Mammalian β-globin Gene Clusters: Combining Phylogenetic Analyses and Experimental Results to Gain Function Insights, Gene, 205:73-94 (1997)	X
Ex.1013	Civin, *et al.*, "Sustained, Retransplantable, Multilineage Engraftment of Highly Purified Adult Human Bone Marrow Stem Cells *In Vivo*," Blood, 88(11):4102-09 (1996)	X
Ex.1014	High, "Gene Therapy in Haematology and Oncology," *Lancet*, 356:S8 (2000)	X
Ex.1015	Ellis, *et al.*, "Evaluation of β-globin Gene Therapy Constructs in Single Copy Transgenic Mice," Nucleic Acids Res., 25(6):1296-1302 (1997)	X
Ex.1016	Li, *et al.*, "Nucleotide Sequence of 16-Kilobase Pairs of DNA 5' to the Human ε-Globin Gene," J. Biol. Chem., 260(28):14901-10 (1985)	X
Ex.1017	Mishima, *et al.*, "The DNA Deletion in an Indian δβ-thalassaemia Begins One Kilobase From the ^{A}γ Globin Gene and Ends in an L1 Repetitive Sequence," Br. J. Haemotol., 73:375-79 (1989)	X
Ex.1018	Vosberg, "Molecular Cloning of DNA: An Introduction Into Techniques and Problems," Hum. Genet. 40(1):1-72 (1977)	X
Ex.1019	Roberts, "Restriction Enzymes and Their Isoschizomers," Nucleic Acids Res., 15(Suppl.):r189-r217 (1987)	X
Ex.1020	Zufferey, *et al.*, "Multiply Attenuated Lentiviral Vector Achieves Efficient Gene Delivery *in Vivo*," Nature Biotech., 15:871-75 (1997)	X
Ex.1021	Miyoshi, *et al.*, "Transduction of Human CD34[+] Cells that Mediate Long-Term Engraftment of NOD/SCID Mice by HIV Vectors," Science, 283:682-86 (1999)	X

Ex.1022	Sadelain, *et. al.*, "Generation of a High-titer Retroviral Vector Capable of Expressing High Levels of the Human β-Globin Gene," Proc. Natl. Acad. Sci. USA, 92:6728-32 (1995)	X
Ex.1023	Bouhassira, *et al.*, "Transcriptional Behavior of LCR Enhancer Elements Integrated at the Same Chromosomal Locus by Recombinase-Mediated Cassette Exchange," Blood 90(9):3332-44 (1997)	X
Ex.1024	Fraser, *et al.*, "Each Hypersensitive Site of the Human β-Globin Locus Control Regions Confers a Different Developmental Pattern of Expression on the Globin Genes," Genes Dev., 7:106-113 (1993)	X
Ex.1025	Engel, "Developmental Regulation of Human β-Globin Gene Transcription: A Switch of Loyalties?," Trend. Genet., 9(9):304-09 (1993)	X
Ex.1026	Roberts & Macelis, "REBASE – Restriction Enzymes and Methylases," Nucleic Acids Res., 26(1):338-350 (1998)	X
Ex.1027	Roberts & Macelis, "REBASE – Restriction Enzymes and Methylases," Nucleic Acids Res., 27(1):312-13 (1999)	X
Ex.1028	Roberts & Macelis, "REBASE – Restriction Enzymes and Methylases," Nucleic Acids Res., 28(1):306-07 (2000)	X
Ex.1029	Roberts & Macelis, "REBASE – Restriction Enzymes and Methylases," Nucleic Acids Res., 29(1):268-69 (2001)	X
Ex.1030	Sequence Manipulation Suite (last visited October 11, 2022) (Website)	X
Ex.1031	Restriction Mapper, April 20, 2001 Wayback Machine Capture (last visited October 11, 2022) (Website)	X
Ex.1032	Prosecution History of the '179 patent (U.S. Patent Application No. 10/188,221)	X
Ex.1033	Prosecution History of the '061 patent (U.S. Patent Application No. 12/433,412)	X

Ex.1034	U.S. Provisional Application 60/301,861 to Sadelain	X
Ex.1035	U.S. Provisional Application 60/302,852 to Sadelain	X
Ex.1036	Declaration by Ingrid Hsieh-Yee, Ph.D.	X
Ex.1037	SciMago, Nature (last visited October 11, 2022) (Website)	X
Ex.1038	SciMago, Molecular Therapy (last visited October 11, 2022) (Website)	X
Ex.1039	SciMago, Journal of Biological Chemistry (last visited October 11, 2022) (Website)	X
Ex.1040	Steele, "Editorial," Mol. Therapy, 1(5):S1 (2000)	X
Ex.1041	Glorioso, "Highlights from the Third Annual ASGT Meeting," Mol. Therapy, 2(2):96-100 (2000)	X
Ex.1042	"Author Index," Mol. Therapy, 1(5):S345-61 (2000)	X
Ex.1043	*San Rocco Therapeutics, LLC v. bluebird bio, Inc. et al.*, C.A. No. 21-1478-RGA, D.I. 75 (D. Del. July 26, 2022)	X
Ex.1044	*San Rocco Therapeutics, LLC v. bluebird bio, Inc. et al.*, C.A. No. 21-1478-RGA, D.I. 76 (D. Del. July 26, 2022)	X
Ex.1045	*San Rocco Therapeutics, LLC v. bluebird bio, Inc. et al.*, C.A. No. 21-1478-RGA, D.I. 78 (D. Del. July 28, 2022)	X
Ex.1046	Vidal, "Interim Procedures for Discretionary Denials in AIA Post-Grant Proceedings with Parallel District Court Litigation (June 21, 2022)	X
Ex.1047	Himanen, *et. al.*, "A Recombinant Sickle Hemoglobin Triple Mutant With Independent Inhibitory Effects on Polymerization." J. Biol. Chem. 271(41):25152-56 (1996) ("*Himanen*")	X
Ex.1048	Declaration of K. Ho ISO Motion for Admission Pro Hac Vice	X

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.